ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution

Westport, CT, Sept. 22, 2020 (GLOBE NEWSWIRE) --

• Size of ongoing Phase 2 trial of merimepodib in combination with remdesivir increased from 40 to 80 subjects, with focus on hospitalized patients requiring non-invasive ventilation/high flow oxygen devices
• Added 2 new Principal Investigators for the ongoing Phase 2 trial expanding the total number of locations to 10
• Contract Manufacturing Organization (CMO) appointed to manufacture Phase 3 supplies of merimepodib oral solution
• Merimepodib monotherapy trial to be conducted in the outpatient setting after current combination trial completes

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc.  (ViralClear), today conducted an investor update call on Viral Clear’s merimepodib drug development program for the treatment of COVID-19.

The size of the ongoing randomized, double-blind, placebo-controlled Phase 2 trial of merimepodib in combination with remdesivir is being increased from 40 to 80 subjects.  When the trial was first initiated, it was thought that COVID-19 patients with National Institute of Allergy and Infectious Disease (NIAID) 8-point ordinal scores of 3 and 4 (i.e., hospitalized patients who require non-invasive ventilation and patients who require high flow oxygen devices and supplemental oxygen, respectively) would have similar outcomes in terms of their disease.  However, based on a review of blinded data from the ongoing trial, subjects with scores of 3 and 4 are showing distinct differences.  All subjects who were admitted with a score of 4 have had an uneventful course of disease and were rapidly discharged from the hospital due to improvement in clinical condition.  The subjects who were admitted with a score of 3 fared differently: one group of subjects improved and were discharged from the hospital and are doing well at long-term follow-up, while others have not improved. 

Based on the above and the small numbers of subjects in each NIAID group, ViralClear decided to increase the enrollment in the current study to 80 subjects, with a focus on subjects with an NIAID score of 3 at entry.  The decision to increase the subject number in the trial was also based on advice from industry experts and discussions with government agencies and non-governmental organizations.  Once additional subjects are enrolled and further clinical data is obtained, the team will discuss with the FDA the appropriate size for a Phase 3 trial.